An Exploratory, Double-blind, Randomized, Placebo-controlled, Single-center, Two-way Cross-over Study With KH176 in Patients With the Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation and Clinical Signs of Mitochondrial Disease
概览
- 阶段
- 2 期
- 干预措施
- KH176
- 疾病 / 适应症
- Mitochondrial Diseases
- 发起方
- Khondrion BV
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Movement disorders
- 状态
- 已完成
- 最后更新
- 8年前
概览
简要总结
Mitochondrial Diseases are rare, progressive, multi-system, often-early fatal disorders affecting both children and adults. KH176 is a novel chemical entity currently under development for the treatment of inherited mitochondrial diseases, including MELAS (Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes), MIDD (Maternally Inherited Diabetes and Deafness), Leigh's Disease and LHON (Leber's Hereditary Optic Neuropathy). The current Proof of Concept study aims to explore the effects of treatment with KH176 for 4 weeks on clinical signs and symptoms and biomarkers of mitochondrial disease and to evaluate the safety and pharmacokinetics of KH176 in patients with m.3242A>G related mitochondrial disease.
详细描述
The trial will be a double blind, randomized, placebo-controlled, single-centre, two-way cross-over trial. Twenty patients, with a confirmed mitochondrial DNA tRNALeu(UUR) m.3243A\>G mutation and with clinical signs of mitochondrial disease, will be randomized over 2 groups (active or placebo first). After a screening period and a training session, each group will have 2 dosing periods of 28 days, with a washout period of at least 28 days in between. On these occasions, patients will receive 100 mg KH176 twice daily (treatment A) or a matching placebo (treatment B) twice daily for 28 days. Clinical assessments will be performed once in a training session prior to baseline, at baseline and in week 4 post dosing during each treatment phase (A and B). Testing conditions and circumstances, with respect to timing of the assessments, hospitalization and meals, will be standardized for each assessement period. Furthermore, assessments of biomarkers for mitochondrial functioning, pharmacokinetics and specific safety assessments will be performed weekly.
研究者
入排标准
入选标准
- •Males and females aged 18 years or older at screening
- •Ability and willingness to sign the Informed Consent Form prior to screening evaluations.
- •Confirmed mitochondrial DNA tRNALeu(UUR) m.3243A\>G mutation
- •Heteroplasmy level as measured in urine ≥ 20 %.
- •Body Mass Index (BMI) 18.0-30.0 kg/m2 (extremes included) at screening
- •Clinical evidence of mitochondrial disease, positive NMDAS score (including but not limited to MELAS, MIDD and mixed types). CPEO patients with signs restricted to the eye only are not considered eligible.
- •Disease appropriate physical and mental health as established by medical history, physical examination, electrocardiogram (ECG) and vital signs recording, and results of biochemistry, hematology and urinalysis testing within 3 weeks prior to the first dose as judged by the Investigator.
- •Appropriate cardiac functioning as assessed by medical history, ECG and Echo, evaluated by a cardiologist.
- •Able to comply with the study requirements, including exercise testing and swallowing study medication
- •Willingness to use adequate contraceptive methods (male and female) and negative urine pregnancy test (females) at screening and first baseline assessment.
排除标准
- •Motoric abnormalities other than related to the mitochondrial disease interfering with the outcome parameters.
- •CPEO patients with clinical signs and symptoms restricted to the eye only
- •Heteroplasmy level as measured in urine \< 20%
- •Poor nutritional state as judged by the investigator
- •Body Mass Index (BMI) not within 18.0-30.0 kg/m2 at screening.
- •History of cancer
- •Surgery or active illness of gastro-intestinal tract that might interfere with absorption.
- •Participation in a trial of an investigational product in the preceding 3 months prior to the first dose or during this trial.
- •Positive drug, alcohol or cotinine test at screening and/or admission (Day 1 of the first dosing period).
- •Clinically relevant abnormal laboratory, ECG recordings, cardiac echo (within 1 year prior to screening), vital signs or physical or mental findings at screening as judged by the Investigator.
研究组 & 干预措施
Treatment A
Oral administration of 100 mg KH176 twice daily
干预措施: KH176
Treatment B
Oral administration of matching placebo twice daily
干预措施: placebo
结局指标
主要结局
Movement disorders
时间窗: one month
Rater assessed change from baseline of motoric abnormalities and movement characteristics
次要结局
- RAND-SF36 score(one month)
- Spirometric parameters (FVC,FEV1, PEF)(one month)
- Spirometric parameters (MIP, MEP)(one month)
- Handgrip Dynamometry(one month)
- HAD and BDI(one month)
- BDI(one month)
- Sit to Stand Test (30 seconds)(one month)
- 6-MWT(one month)
- NMDAS(one month)
- 6-min chewing test(one month)
- CIS(one month)
- Goal Attainment Scale(one month)
- Registration of Motor Activity and Sleeping pattern(one month)
- Vital Signs(one month)
- Clinical Laboratory(one month)
- Pharmacokinetics of KH176 and metabolites(one month)
- TAP(one month)
- ECG(one month)
- Glutathione(one month)
- Blood biomarker FGF21(one month)
- Blood biomarker GDF15(one month)
- Blood biomarker PRDX1(one month)